Start-Up Quarterly Statistics, Q1 2014

Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.

During the first quarter of 2014 start-up companies raised $1.18 billion, up $2.8 million from last quarter’s impressive total and setting a new record for start-up fundraising since we began featuring this column five years ago. Biopharma companies pulled in 92% ($1.08 billion), of which 59% was the result of public financings. Eight medical device firms together generated $75.2 million, while only two in vitro diagnostics companies raised a combined $23.1 million (down from the $81 million in Q4 2013). (See Exhibit 1.)

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By 

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By 

The biotech had been looking at options to survive since May.

Kymera Inks CDK2 Deal With Gilead

 

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

More from Business

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By 

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

US Tariff Overhang Weighs on Chinese API Exports

 

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.